कृपया अन्य खोज का प्रयास करें
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Masashi Miyamoto | 62 | 2011 | President, CEO & Representative Director |
Akira Morita | - | 2019 | Outside Independent Chairman |
Tomomi Yatsu | 63 | 2021 | Outside Independent Auditor |
Yuko Haga | 69 | 2019 | Independent Outside Director |
Yutaka Osawa | 65 | 2017 | CCO, Executive VP & Representative Director |
Hiroshi Komatsu | 62 | 2018 | Full-time Audit & Supervisory Board Member |
Rumiko Nakata | 68 | 2023 | Independent Outside Director |
Shinjiro Akieda | 59 | 2024 | Director |
Yoshihisa Q. Suzuki | 69 | 2022 | Independent Outside Director |
Takashi Oyamada | 69 | 2021 | Independent Outside Director |
Tomomi Yatsu | 64 | 2021 | Outside Audit & Supervisory Board Member |
Mayumi Tamura | 64 | 2022 | Outside Audit & Supervisory Board Member |
Toru Ishikura | 61 | 2023 | Audit & Supervisory Board Member |
Hajime Kobayashi | 59 | - | Outside Audit & Supervisory Board Member |
Takeyoshi Yamashita | 63 | 2021 | Chief Medical Officer, Senior Managing Executive Officer & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है